These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 29493134)
1. [Research advances on astragaloside-IV in treatment of diabetes mellitus and its complications pharmacological effects]. You LZ; Lin YX; Fang ZH; Shen GM; Zhao JD; Wang TT Zhongguo Zhong Yao Za Zhi; 2017 Dec; 42(24):4700-4706. PubMed ID: 29493134 [TBL] [Abstract][Full Text] [Related]
2. Biological active ingredients of traditional Chinese herb Astragalus membranaceus on treatment of diabetes: a systematic review. Zhang K; Pugliese M; Pugliese A; Passantino A Mini Rev Med Chem; 2015; 15(4):315-29. PubMed ID: 25723453 [TBL] [Abstract][Full Text] [Related]
3. Pharmacological effects of Astragaloside IV: a literature review. Ren S; Zhang H; Mu Y; Sun M; Liu P J Tradit Chin Med; 2013 Jun; 33(3):413-6. PubMed ID: 24024343 [TBL] [Abstract][Full Text] [Related]
4. Astragaloside IV attenuates fatty acid-induced renal tubular injury in diabetic kidney disease by inhibiting fatty acid transport protein-2. Wang J; Wang L; Feng X; Xu Y; Zhou L; Wang C; Wang M Phytomedicine; 2024 Nov; 134():155991. PubMed ID: 39217653 [TBL] [Abstract][Full Text] [Related]
5. Astragaloside IV derived from Astragalus membranaceus: A research review on the pharmacological effects. Zhang J; Wu C; Gao L; Du G; Qin X Adv Pharmacol; 2020; 87():89-112. PubMed ID: 32089240 [TBL] [Abstract][Full Text] [Related]
6. Research review on the pharmacological effects of astragaloside IV. Li L; Hou X; Xu R; Liu C; Tu M Fundam Clin Pharmacol; 2017 Feb; 31(1):17-36. PubMed ID: 27567103 [TBL] [Abstract][Full Text] [Related]
7. The beneficial effects of astragaloside IV on ameliorating diabetic kidney disease. Gao Y; Su X; Xue T; Zhang N Biomed Pharmacother; 2023 Jul; 163():114598. PubMed ID: 37150034 [TBL] [Abstract][Full Text] [Related]
8. Astragaloside IV attenuates proteinuria in streptozotocin-induced diabetic nephropathy via the inhibition of endoplasmic reticulum stress. Wang ZS; Xiong F; Xie XH; Chen D; Pan JH; Cheng L BMC Nephrol; 2015 Mar; 16():44. PubMed ID: 25886386 [TBL] [Abstract][Full Text] [Related]
9. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Wang E; Wang L; Ding R; Zhai M; Ge R; Zhou P; Wang T; Fang H; Wang J; Huang J Pharmacol Res; 2020 Jul; 157():104831. PubMed ID: 32339782 [TBL] [Abstract][Full Text] [Related]
10. Administration of Traditional Chinese Blood Circulation Activating Drugs for Microvascular Complications in Patients with Type 2 Diabetes Mellitus. He L; Wang H; Gu C; He X; Zhao L; Tong X J Diabetes Res; 2016; 2016():1081657. PubMed ID: 27830156 [TBL] [Abstract][Full Text] [Related]
11. Astragaloside IV prevents high glucose‑induced cell apoptosis and inflammatory reactions through inhibition of the JNK pathway in human umbilical vein endothelial cells. You L; Fang Z; Shen G; Wang Q; He Y; Ye S; Wang L; Hu M; Lin Y; Liu M; Jiang A Mol Med Rep; 2019 Mar; 19(3):1603-1612. PubMed ID: 30628687 [TBL] [Abstract][Full Text] [Related]
12. Profiling the metabolism of astragaloside IV by ultra performance liquid chromatography coupled with quadrupole/time-of-flight mass spectrometry. Cheng XD; Wei MG Molecules; 2014 Nov; 19(11):18881-96. PubMed ID: 25407723 [TBL] [Abstract][Full Text] [Related]
13. Research progress of the effective active ingredients of Astragalus mongholicus in the treatment of diabetic peripheral neuropathy. Liu Y; Yu R; Wang X; Chen Y; Yin T; Gao Q; Sun L; Zheng Z Biomed Pharmacother; 2024 Apr; 173():116350. PubMed ID: 38430632 [TBL] [Abstract][Full Text] [Related]
14. Astragaloside IV: An Effective Drug for the Treatment of Cardiovascular Diseases. Tan YQ; Chen HW; Li J Drug Des Devel Ther; 2020; 14():3731-3746. PubMed ID: 32982178 [TBL] [Abstract][Full Text] [Related]
15. Recent pharmacological advances in the treatment of cardiovascular events with Astragaloside IV. Xu Z; Zhou H; Zhang Y; Cheng Z; Wan M; Qin W; Li P; Feng J; Shao S; Xue W; Guo H; Liu B Biomed Pharmacother; 2023 Dec; 168():115752. PubMed ID: 37875045 [TBL] [Abstract][Full Text] [Related]
16. Astragaloside IV improves vascular endothelial dysfunction by inhibiting the TLR4/NF-κB signaling pathway. Leng B; Tang F; Lu M; Zhang Z; Wang H; Zhang Y Life Sci; 2018 Sep; 209():111-121. PubMed ID: 30081006 [TBL] [Abstract][Full Text] [Related]
17. Astragaloside suppresses tumor necrosis factor receptor-associated factor 5 signaling pathway and alleviates neurodegenerative changes in retinal pigment epithelial cells induced by isoflurane. Chen PJ; Shang AQ; Wang WW; Yang JP J Cell Biochem; 2019 Jan; 120(1):1028-1037. PubMed ID: 30277612 [TBL] [Abstract][Full Text] [Related]
18. Astragaloside IV ameliorates early diabetic nephropathy by inhibition of MEK1/2-ERK1/2-RSK2 signaling in streptozotocin-induced diabetic mice. Song G; Han P; Sun H; Shao M; Yu X; Wang W; Wang D; Yi W; Ge N; Li S; Yi T J Int Med Res; 2018 Jul; 46(7):2883-2897. PubMed ID: 29896981 [TBL] [Abstract][Full Text] [Related]
19. Astragaloside IV inhibits proliferation and promotes apoptosis in rat vascular smooth muscle cells under high glucose concentration in vitro. Yuan W; Zhang Y; Ge Y; Yan M; Kuang R; Zheng X Planta Med; 2008 Aug; 74(10):1259-64. PubMed ID: 18622899 [TBL] [Abstract][Full Text] [Related]
20. Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin. Lv L; Wu SY; Wang GF; Zhang JJ; Pang JX; Liu ZQ; Xu W; Wu SG; Rao JJ Phytother Res; 2010 Feb; 24(2):219-24. PubMed ID: 19610026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]